<DOC>
	<DOCNO>NCT02697734</DOCNO>
	<brief_summary>Purpose study aim confirm efficacy safety osilodrostat treatment patient Cushing 's disease candidate medical therapy</brief_summary>
	<brief_title>Efficacy Safety Evaluation Osilodrostat Cushing 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<criteria>Key inclusion criterion : Confirmed CD persistent recurrent evidence follow criterion meet ( i.e. , , b c ) : 1. mUFC &gt; 1.3 x ULN ( Mean three 24hour urine sample collect preferably 3 consecutive day , screen washout prior medical therapy CD ( applicable ) , confirmed central laboratory available Day 1 ) , ≥2 individual UFC value &gt; 1.3 x ULN . 2 . Morning plasma ACTH Lower Limit Normal 3 . Confirmation ( base medical history ) pituitary source excess ACTH define one follow three criterion : i. Histopathologic confirmation ACTHstaining adenoma patient prior pituitary surgery . OR ii . MRI confirmation pituitary adenoma &gt; 6 mm OR iii . Bilateral inferior petrosal sinus sampling ( BIPSS ) either CRH DDAVP stimulation patient tumor ≤ 6mm . The criterion confirmatory BIPSS test following : Predose central peripheral ACTH gradient &gt; 2 ; Postdose central peripheral ACTH gradient &gt; 3 either CRH DDAVP stimulation Patients receive glucocorticoid replacement therapy must discontinue therapy least seven day 5 halflives prior screen , whichever longer . Patients de novo CD include consider candidate surgery ( e.g. , poor surgical candidate due comorbidities , inoperable tumor , patient refuse surgical treatment , surgical treatment available ) . Key exclusion criterion : Patients pseudoCushing 's syndrome . This may diagnose normal late night salivary cortisol value collect screening period washout prior CD medication . Patients risk factor QTc prolongation Torsade de Pointes , include : patient baseline QTcF &gt; 450 m male QTcF &gt; 460 m female ; personal family history long QT syndrome ; concomitant medication know prolong QT interval ; patient hypokalemia , hypocalcaemia , hypomagnesaemia , correct predose Day 1 . Patients likely require adrenalectomy , pituitary surgery , radiation therapy placebocontrolled period ( Weeks 112 ) treatment severe hypercortisolism pituitary tumor growth cause compression optic chiasm . Patients compression optic chiasm due macroadenoma patient high risk compression optic chiasm ( tumor within 2 mm optic chiasm ) . Patients know inherited syndrome cause hormone secretion ( i.e . Carney Complex , McCuneAlbright syndrome , MEN1 , AIP ) . Patients Cushing 's syndrome due ectopic ACTH secretion ACTH independent ( adrenal ) Cushing 's syndrome . Pregnant nursing ( lactate ) woman . 8 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 1 week completion dose . Highly effective contraception method include : A . Total abstinence ( line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . B . Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study drug . In case bilateral oophorectomy , documentation require ( e.g . operative report , pelvic ultrasound reliable image method ) . C. Male sterilization ( least 6 month prior screen ) . For female subject study vasectomized male partner sole partner subject . D. Combination two follow ( a+b a+c , b+c ) : 1 . Use oral* , inject , implanted hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) 3 . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository . *In case use oral contraception , woman stable pill minimum 3 month take study drug . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( i.e. , age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) , total hysterectomy , tubal ligation least six week ago . In case oophorectomy alone , reproductive status woman confirm followup hormone level assessment consider child bear potential . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cushing 's disease</keyword>
	<keyword>LCI699</keyword>
	<keyword>osilodrostat</keyword>
	<keyword>Pituitary Gland</keyword>
	<keyword>Adrenocorticotropic</keyword>
	<keyword>Hormone</keyword>
	<keyword>ACTH</keyword>
	<keyword>UFC</keyword>
</DOC>